Related references
Note: Only part of the references are listed.A Vitamin D Receptor/SMAD Genomic Circuit Gates Hepatic Fibrotic Response
Ning Ding et al.
CELL (2013)
Evaluation of the potential therapeutic role of a new generation of vitamin D analog, MART-10, in human pancreatic cancer cells in vitro and in vivo
Kun-Chun Chiang et al.
CELL CYCLE (2013)
Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studies
Amnon C. Sintov et al.
INVESTIGATIONAL NEW DRUGS (2013)
Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis
Hiroshi Hagino et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2013)
Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin
Jason Gee et al.
PROSTATE (2013)
Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone
Suguru Harada et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats
Soochan Bae et al.
CARDIOVASCULAR RESEARCH (2011)
The Vitamin D Analog, TX527, Promotes a Human CD4(+)CD25(high)CD127(low) Regulatory T Cell Profile and Induces a Migratory Signature Specific for Homing to Sites of Inflammation
Femke Baeke et al.
JOURNAL OF IMMUNOLOGY (2011)
1 alpha,25-Dihydroxyvitamin D-3 and Its TX527 Analog Inhibit the Growth of Endothelial Cells Transformed by Kaposi Sarcoma-Associated Herpes Virus G Protein-Coupled Receptor in Vitro and in Vivo
Veronica Gonzalez-Pardo et al.
ENDOCRINOLOGY (2010)
EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells
Vandanajay Bhatia et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Superagonistic Fluorinated Vitamin D3 Analogs Stabilize Helix 12 of the Vitamin D Receptor
Guy Eelen et al.
CHEMISTRY & BIOLOGY (2008)
Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer
Steven Attia et al.
CLINICAL CANCER RESEARCH (2008)
A vitamin D analogue inhibits colonic carcinogenesis in the AOM/DSS model
Alessandro Fichera et al.
JOURNAL OF SURGICAL RESEARCH (2007)
Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD
D Coyne et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2006)
Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction
G Eelen et al.
MOLECULAR PHARMACOLOGY (2005)
Gene expression profiles in dendritic cells conditioned by lα,25-dihydroxyvitamin D3 analog
MD Griffin et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2004)
Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4
JW Coburn et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2004)
Effectiveness of vitamin D analogues in treating large tumors and during prolonged use in murine retinoblastoma models
DM Albert et al.
ARCHIVES OF OPHTHALMOLOGY (2004)
Effectiveness of 1α-hydroxyvitamin D2 in inhibiting tumor growth in a murine transgenic pigmented ocular tumor model
DM Albert et al.
ARCHIVES OF OPHTHALMOLOGY (2004)
A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma
K Dalhoff et al.
BRITISH JOURNAL OF CANCER (2003)
Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion
L Flanagan et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2003)
Toxicity and dose-response studies of 1α-hydroxyvitamin D2 in a retinoblastoma xenograft model
RJ Grostern et al.
ARCHIVES OF OPHTHALMOLOGY (2002)
Share Paper
